• Ensysce outlined commercialization strategy centered on TAAP and MPAR platforms designed to provide abuse deterrence and overdose protection using trypsin-controlled activation.
• Lead candidate PF614 targets acute severe pain with Phase 3 program underway, including PF614-301 initiated in 2025.
• Company plans to initiate PF614-302 open-label bunionectomy study in 2026 to expand safety database supporting PF614 NDA targeted for 2027.
• PF614-MPAR, combination of PF614 with trypsin inhibitor nafamostat, is positioned for chronic pain with Phase 1 data presented as demonstrating overdose protection.
• Pipeline update highlighted FDA Fast Track designation for PF614 granted in January 2018, followed by FDA Breakthrough Therapy designation for TAAP oxycodone combination product granted in January 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.